Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9773 | 0.77 | SMN1; SMN2 (0.69) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL10669530 | 0.76 | SMN1; SMN2 (0.67) | GAAL3MBTL1MAPTSMN1; SMN2POLB | |
| SCHEMBL5247667 | 0.76 | SMN1; SMN2 (0.71) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL1186765 | 0.76 | SMN1; SMN2 (0.71) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL9706226 | 0.75 | SMN1; SMN2 (0.60) | GAAL3MBTL1MAPTGLASMN1; SMN2 | |
| SCHEMBL7750031 | 0.75 | SMN1; SMN2 (0.65) | L3MBTL1SMN1; SMN2POLBALOX15ALDH1A1 | |
| SCHEMBL14590051 | 0.75 | SMN1; SMN2 (0.65) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL1690435 | 0.75 | HPGD (0.68) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL1186533 | 0.74 | SMN1; SMN2 (0.69) | GAAMAPTSMN1; SMN2POLBTDP1 | |
| SCHEMBL30585275 | 0.74 | SMN1; SMN2 (0.69) | MAPTSMN1; SMN2POLBTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | CHIRON CORPORATION | 2004-02-19 | — | — | US | disclosed |
| US-20020111374-A1 | Estrogen receptor modulators | CHIRON CORPORATION | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034081-A9 | ESTROGEN RECEPTOR MODULATORS | ESR1, ESR2, GPER1 | GAA 3654/4885L3MBTL1 4707/4885MAPT 1269/4885 |
| US-20020111374-A1 | Estrogen receptor modulators | ESR1, ESR2, GPER1 | GAA 3654/4885L3MBTL1 4707/4885MAPT 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.